[go: up one dir, main page]

AR066958A1 - Imidazopirazinas como inhibidores de proteina quinasa - Google Patents

Imidazopirazinas como inhibidores de proteina quinasa

Info

Publication number
AR066958A1
AR066958A1 ARP080102481A ARP080102481A AR066958A1 AR 066958 A1 AR066958 A1 AR 066958A1 AR P080102481 A ARP080102481 A AR P080102481A AR P080102481 A ARP080102481 A AR P080102481A AR 066958 A1 AR066958 A1 AR 066958A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
alkylc
heteroaryl
aryl
Prior art date
Application number
ARP080102481A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40002934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066958(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR066958A1 publication Critical patent/AR066958A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP080102481A 2007-06-14 2008-06-11 Imidazopirazinas como inhibidores de proteina quinasa AR066958A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94399907P 2007-06-14 2007-06-14
US98793207P 2007-11-14 2007-11-14

Publications (1)

Publication Number Publication Date
AR066958A1 true AR066958A1 (es) 2009-09-23

Family

ID=40002934

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102481A AR066958A1 (es) 2007-06-14 2008-06-11 Imidazopirazinas como inhibidores de proteina quinasa

Country Status (10)

Country Link
EP (1) EP2170892A2 (fr)
JP (1) JP2010529195A (fr)
CN (1) CN101772500A (fr)
AR (1) AR066958A1 (fr)
CA (1) CA2690557A1 (fr)
CL (1) CL2008001745A1 (fr)
MX (1) MX2009013729A (fr)
PE (1) PE20090365A1 (fr)
TW (1) TW200911811A (fr)
WO (1) WO2008156614A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175195A1 (en) 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
ES2555261T3 (es) * 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
ES2541054T3 (es) * 2010-10-20 2015-07-15 Université De Bordeaux Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales
EP2444084A1 (fr) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Utilisation d'inhibiteurs de PI3K pour le traitement de l'obésité
WO2012052745A1 (fr) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinaisons d'inhibiteurs de pi3k avec un second agent antitumoral
JP2013545776A (ja) * 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
US8673905B2 (en) * 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
JP2014521595A (ja) 2011-05-25 2014-08-28 ブリストル−マイヤーズ スクイブ カンパニー 抗アポトーシスＢｃｌ阻害剤として有用な置換スルホンアミド
WO2013000924A1 (fr) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]quinoxaline
WO2014001314A1 (fr) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinaisons comprenant des inhibiteurs de la pde 2 tels que des composés 1-aryl-4-méthyl-[1, 2, 4] triazolo [4, 3-a]-quinoxaline et des inhibiteurs de la pde 10 pour utilisation dans le traitement de troubles neurologiques ou métaboliques
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
PL3805233T3 (pl) 2014-01-13 2024-06-10 Aurigene Oncology Limited ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego
WO2015123437A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
ME03654B (fr) 2014-02-13 2020-07-20 Incyte Corp Cyclopropylamines en tant qu'inhibiteurs de lsd1
PT3105226T (pt) 2014-02-13 2019-11-06 Incyte Corp Ciclopropilaminas como inibidores de lsd1
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
AR109452A1 (es) 2016-04-22 2018-12-12 Incyte Corp Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
CN120267671A (zh) * 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
CN107954977A (zh) * 2017-12-15 2018-04-24 上海鼎雅药物化学科技有限公司 雷替曲塞中间体的合成方法
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
EA202191422A1 (ru) 2018-11-21 2021-10-21 Кейс Вестерн Ризерв Юниверсити Композиции и способы модулирования активности короткоцепочечной дегидрогеназы
JP7771084B2 (ja) * 2020-04-29 2025-11-17 エフ． ホフマン－ラ ロシュ アーゲー 抗菌８－フェニルアミノ－３－（ピラゾール－４－イル）イミダゾ［１，２－ａ］ピラジン誘導体
CN116113406B (zh) * 2020-07-10 2025-08-29 密歇根大学董事会 Gas41抑制剂及其使用方法
CN117120054A (zh) 2021-04-08 2023-11-24 柯里斯公司 治疗癌症的组合疗法
WO2022222995A1 (fr) * 2021-04-23 2022-10-27 南京明德新药研发有限公司 Composé picolinamide
WO2023169438A1 (fr) * 2022-03-07 2023-09-14 上海凌达生物医药有限公司 Composés inhibiteurs du cycle cellulaire hétérocyclique contenant de l'azote, leur procédé de préparation et leur utilisation
WO2024088192A1 (fr) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. Inhibiteur d'aurora a destiné à être utilisé dans des traitements anticancéreux

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
TW200413378A (en) * 2002-09-23 2004-08-01 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
SG159549A1 (en) * 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
BRPI0618520A2 (pt) * 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase

Also Published As

Publication number Publication date
JP2010529195A (ja) 2010-08-26
CA2690557A1 (fr) 2008-12-24
PE20090365A1 (es) 2009-04-04
WO2008156614A3 (fr) 2009-02-12
EP2170892A2 (fr) 2010-04-07
CL2008001745A1 (es) 2008-12-05
MX2009013729A (es) 2010-01-25
WO2008156614A2 (fr) 2008-12-24
TW200911811A (en) 2009-03-16
CN101772500A (zh) 2010-07-07

Similar Documents

Publication Publication Date Title
AR066958A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
AR063581A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
EP4373939A4 (fr) Compositions d'édition de génome et méthodes de traitement de maladie granulomateuse chronique
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
CY1124346T1 (el) ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ
EP4384219A4 (fr) Compositions, posologies et méthodes pour le traitement d'une maladie oculaire thyroïdienne
EA201201414A8 (ru) КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
UY30032A1 (es) Compuestos de cinolina, composiciones farmacéuticas que los contienen y procesos para la preparación y uso de los mismos
EP4126038A4 (fr) Compositions de vaccin pour le traitement du coronavirus
EA202193334A1 (ru) Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
BR112022020933A2 (pt) Inibidores de replicação do vírus da imunodeficiência humana
EP4438048A4 (fr) Composition pharmaceutique de traitement ou de prévention de troubles liés aux lymphocytes t
EP4423288A4 (fr) Compositions et méthodes d'administration thérapeutique ou vaccinale
EP4000609A4 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies osseuses
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
DK4426307T3 (da) Ny oral farmaceutisk sammensætning og doseringsplan til behandling af progressive fibroserende interstitielle lungesygdomme
CO2021001174A2 (es) Inhibidores de ckd8/19
EP4034082A4 (fr) Composition pharmaceutique orale à libération immédiate et méthode de traitement de perte de poids

Legal Events

Date Code Title Description
FA Abandonment or withdrawal